Invesco
CRVS icon

Invesco’s Corvus Pharmaceuticals CRVS Stock Holding History

Invesco’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$623K Buy
41,702
+3,490
+9% +$48.4K ﹤0.01% 3155
2026
Q1 		$559K Sell
38,212
-5,371
-12% -$85.7K ﹤0.01% 3119
2025
Q4 		$336K Buy
43,583
+4,910
+13% +$38.7K ﹤0.01% 3343
2025
Q3 		$285K Sell
38,673
-1,934
-5% -$9.9K ﹤0.01% 3439
2025
Q2 		$162K Buy
+40,607
New +$148K ﹤0.01% 3569
2023
Q4 		– Sell
-15,617
Closed -$22.8K – 3841
2023
Q3 		$22.8K Buy
15,617
+4,672
+43% +$9.88K ﹤0.01% 3853
2023
Q2 		$25.1K Buy
+10,945
New +$22.7K ﹤0.01% 3853

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Invesco's CRVS Position: Q2 2026 in Review

Invesco increased its Corvus Pharmaceuticals (CRVS) stake by 9.1% in Q2 2026, buying an estimated $48.4K and bringing the position to 41,702 shares worth $623K. The position accounts for ﹤0.01% of the portfolio, ranked #3155.

Invesco first reported a position in CRVS in Q2 2023 and has held it in 7 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Invesco held 41,702 shares of Corvus Pharmaceuticals worth $623K as of Q2 2026.
  • Invesco bought 3,490 Corvus Pharmaceuticals shares in Q2 2026, an estimated $48.4K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3155 holding.
  • Invesco first reported a position in Corvus Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.